Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma
NCT ID: NCT06851221
Last Updated: 2025-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
95 participants
INTERVENTIONAL
2020-08-05
2024-03-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma
NCT01609803
Biomarkers in Samples From Young Patients With Neuroblastoma
NCT01358604
Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma
NCT01374672
Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
NCT04621201
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
biological samples analysis
beta3 expression
the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
beta3 expression
the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
0 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meyer Children's Hospital IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maura Calvani
Head of Traslational oncoematology laboratory
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratorio traslazionale in oncoematologia
Florence, Italy, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BETA3TumPed
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.